Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
October 1, 2018
To access the live webcast, please visit ir.nightstartx.com. A replay of the webcast will be available on the Nightstar website for two weeks following the conference.
Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar’s lead product candidate, NSR-REP1, is currently in Phase 3 development for the treatment of patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments. Results from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in 2014 and in
For more information about Nightstar or its clinical trials, please visit www.nightstartx.com.
Source: Nightstar Therapeutics